Dia Beta Labs

Executive Summary

Dia Beta Labs is a UK-based preclinical biotech company founded in 2019, leveraging over 30 years of translational research from Ulster University to develop novel peptide therapeutics for metabolic diseases. The company's primary focus is on halting the progression of Type 2 Diabetes by targeting pancreatic beta-cell health, aiming to address the underlying decline in insulin-producing cells rather than merely managing symptoms. Operating at the preclinical stage, Dia Beta Labs has not yet disclosed specific pipeline candidates or funding details, but its approach represents a potential paradigm shift in diabetes treatment by preserving beta-cell function and mass. As a private, early-stage company with no publicly available financial or pipeline data, Dia Beta Labs faces significant development and financing risks. However, its strong academic foundation and clear therapeutic hypothesis provide a compelling basis for further investment. The coming 12-18 months will be critical, as the company seeks to generate preclinical proof-of-concept data, secure Series A financing, and advance toward IND-enabling studies. Success in these milestones could position Dia Beta Labs as a key player in the next generation of diabetes therapies.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data in Type 2 Diabetes Models30% success
• Q4 2026Series A Financing Round40% success
• Q1 2027Initiation of IND-Enabling Studies25% success